alphaveTORNTPHARM₹4,925.00

Torrent Pharmaceuticals Ltd.

₹ CrorePeersSUNPHARMA JBCHEPHARM MANKIND ZYDUSLIFE DIVISLAB MAXHEALTH DRREDDY CIPLAMcap ₹1.67L Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Returns
Return on Common Equity	24.15	25.17	12.30	12.30
Return on Assets	11.00	12.75	4.82	4.82
Return on Capital Employed	26.57	28.48	9.56	9.56
Return on Invested Capital	18.36	21.06	8.42	9.10
Margins
EBITDA Margin	31.39	32.31	32.61	33.02
Operating Margin	23.86	25.41	24.61	24.61
Incremental Operating Margin	—	46.45	20.86	—
Pretax Margin	21.92	23.21	20.54	18.23
Net Income Margin	15.44	16.59	15.29	13.71
Net Income to Common Margin	15.44	16.59	15.47	13.87
FCF Margin	26.41	17.14	16.78	16.78
Additional
Effective Tax Rate	29.59	28.51	25.56	24.80
Dvd Payout Ratio	61.29	56.67	60.29	—
Sustainable Growth Rate	9.35	10.91	4.88	12.30
Incremental Operating Margin %	46.45	20.86	13.77	—

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.